CA2481186C - Bacteries gram negatives attenuees - Google Patents

Bacteries gram negatives attenuees Download PDF

Info

Publication number
CA2481186C
CA2481186C CA2481186A CA2481186A CA2481186C CA 2481186 C CA2481186 C CA 2481186C CA 2481186 A CA2481186 A CA 2481186A CA 2481186 A CA2481186 A CA 2481186A CA 2481186 C CA2481186 C CA 2481186C
Authority
CA
Canada
Prior art keywords
leu
ala
ile
lys
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2481186A
Other languages
English (en)
Other versions
CA2481186A1 (fr
Inventor
Helen Rachel Crooke
Jacqueline Elizabeth Shea
Robert Graham Feldman
Sylvain Gabriel Goutebroze
Francois-Xavier Le Gros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Merial LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial LLC filed Critical Merial LLC
Publication of CA2481186A1 publication Critical patent/CA2481186A1/fr
Application granted granted Critical
Publication of CA2481186C publication Critical patent/CA2481186C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un mutant d'une bactérie gram négative, cette bactérie possédant au moins une mutation dans une séquence nucléotidique codant un polypeptide d'une identité supérieure ou égale à 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, ou 99 % avec une séquence d'acides aminés codée par une séquence nucléotidique choisie dans le groupe comprenant les séquences nucléotidiques appelées SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93. Cette mutation a pour résultat une virulence atténuée de la bactérie. L'invention concerne également des compositions immunogènes ainsi que des vaccins contenant un tel mutant.
CA2481186A 2002-04-05 2003-04-04 Bacteries gram negatives attenuees Expired - Lifetime CA2481186C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37028202P 2002-04-05 2002-04-05
US60/370,282 2002-04-05
US10/406,686 US7449178B2 (en) 2002-04-05 2003-04-03 Attenuated gram negative bacteria
US10/406,686 2003-04-03
PCT/US2003/010308 WO2003086277A2 (fr) 2002-04-05 2003-04-04 Bacteries gram negatives attenuees

Publications (2)

Publication Number Publication Date
CA2481186A1 CA2481186A1 (fr) 2003-10-23
CA2481186C true CA2481186C (fr) 2015-10-06

Family

ID=29254405

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2481186A Expired - Lifetime CA2481186C (fr) 2002-04-05 2003-04-04 Bacteries gram negatives attenuees

Country Status (16)

Country Link
US (3) US7449178B2 (fr)
EP (1) EP1575483B1 (fr)
JP (1) JP4338528B2 (fr)
KR (1) KR101037566B1 (fr)
CN (2) CN1934240A (fr)
AT (1) ATE518955T1 (fr)
AU (2) AU2003223447C1 (fr)
BR (1) BRPI0309001B1 (fr)
CA (1) CA2481186C (fr)
CO (1) CO5640065A1 (fr)
ES (1) ES2371498T3 (fr)
HK (1) HK1078271A1 (fr)
MX (1) MXPA04009730A (fr)
NZ (1) NZ535993A (fr)
PT (1) PT1575483E (fr)
WO (1) WO2003086277A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG119177A1 (en) * 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
JP2002524077A (ja) * 1998-09-04 2002-08-06 クリートゲン アクチエンゲゼルシャフト 抗原キャリヤーとしての弱毒化サルモネラspi2突然変異体
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
DK1350796T3 (da) * 2002-04-05 2009-03-02 Merial Sas Attenuerede gramnegative bakterier
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
ZA200509533B (en) * 2003-07-02 2007-03-28 Us Biotechnology Res And Dev Corp Acapsular P. multocida hyaE deletion mutants
EP1831248B1 (fr) 2004-12-22 2010-12-15 Intervet International BV Vaccin de pasteurella multocida
US8703153B2 (en) 2008-06-16 2014-04-22 Prokarium Ltd. Salmonella vectored vaccines against Chlamydia and methods of use
US8917497B2 (en) * 2012-07-23 2014-12-23 Knaack Llc Jobsite storage cabinet for housing electronic equipment
US9757445B2 (en) 2013-11-01 2017-09-12 Merial Inc. Attenuated Pasteurella multocida vaccines and methods of making and use thereof
WO2016049917A1 (fr) * 2014-09-30 2016-04-07 Bgi Shenzhen Co., Limited Biomarqueurs pour les maladies liées à l'obésité
TW202219269A (zh) * 2020-09-30 2022-05-16 美國農業部 新型多殺性巴斯德氏菌株及具有hyaC與nanP缺失之疫苗
TW202214294A (zh) * 2020-09-30 2022-04-16 美商碩騰服務公司 具有hyaC及nanP缺失之新穎多殺性巴斯德氏菌株及疫苗

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0668779A4 (fr) * 1992-11-06 1996-08-21 Univ Minnesota COMPOSITION PROTEGEANT DE L'INFECTION PAR LA PASTEURELLOSE A -i(P. MULTOCIDA).
US6793927B1 (en) * 1993-12-06 2004-09-21 The United States Of America As Represented By The Secretary Of The Department Of Agriculture Construction of Pasteurella haemolytica vaccines
SG119177A1 (en) 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
ZA974809B (en) * 1996-05-31 1998-01-23 Akzo Nobel Nv Live attenuated RTX-producing bacteria of the family pasteurellaceae.
US6086894A (en) * 1996-06-27 2000-07-11 Virginia Tech Intellectual Properties, Inc. Recombinant vaccine for diseases caused by encapsulated organisms
US6783764B1 (en) * 1997-04-10 2004-08-31 Akzo Nobel Nv Actinobacillus pleuropneumoniae subunit vaccine
CH692179A5 (de) 1997-06-25 2002-03-15 Kueschall Design Ag Rollstuhl und Sitzmodul für den Rollstuhl,
US20010018055A1 (en) * 1997-09-25 2001-08-30 Briggs Robert E. Deletion mutants of virulence factors of pasteurellaceae
CN1351653A (zh) * 1999-04-09 2002-05-29 法玛西雅厄普约翰美国公司 抗细菌疫苗组合物
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
US6780405B1 (en) * 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
WO2002018601A2 (fr) * 2000-08-25 2002-03-07 Abbott Laboratories Genes bacteriens essentiels et lecture du genome dans haemophilius influenzae pour l'identification de 'genes essentiels'
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
DK1350796T3 (da) * 2002-04-05 2009-03-02 Merial Sas Attenuerede gramnegative bakterier
US7449178B2 (en) 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
CA2520386A1 (fr) * 2003-03-27 2004-10-14 Children's Hospital, Inc. Facteur de virulence d'hemophilus influenzae non classifiable en type
UA100370C2 (uk) * 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
TWI328458B (en) * 2007-03-09 2010-08-11 Univ Nat Chunghsing Subunit vaccine of pasteurella multocida in veterinary uses

Also Published As

Publication number Publication date
WO2003086277A9 (fr) 2006-02-23
WO2003086277A3 (fr) 2007-03-01
HK1078271A1 (en) 2006-03-10
US20120009218A1 (en) 2012-01-12
NZ535993A (en) 2010-02-26
PT1575483E (pt) 2011-09-08
CN1934240A (zh) 2007-03-21
AU2003223447A1 (en) 2003-10-27
US7449178B2 (en) 2008-11-11
EP1575483A4 (fr) 2007-07-04
ES2371498T3 (es) 2012-01-03
US8329163B2 (en) 2012-12-11
EP1575483A2 (fr) 2005-09-21
KR20050016334A (ko) 2005-02-21
AU2003223447B2 (en) 2010-06-03
CN102864090A (zh) 2013-01-09
BRPI0309001B1 (pt) 2021-11-30
JP2005535296A (ja) 2005-11-24
MXPA04009730A (es) 2006-04-28
CA2481186A1 (fr) 2003-10-23
JP4338528B2 (ja) 2009-10-07
CO5640065A1 (es) 2006-05-31
BRPI0309001A2 (pt) 2017-07-04
ATE518955T1 (de) 2011-08-15
EP1575483B1 (fr) 2011-08-03
WO2003086277A2 (fr) 2003-10-23
US7943125B2 (en) 2011-05-17
KR101037566B1 (ko) 2011-05-27
AU2003223447C1 (en) 2011-01-06
AU2010206113B2 (en) 2012-03-15
US20040033586A1 (en) 2004-02-19
AU2010206113A1 (en) 2010-08-26
US20090252766A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
US8329163B2 (en) Attenuated gram negative bacteria
KR100802198B1 (ko) 신규한 스트렙토코커스 항원
AU2005203189B2 (en) Anti-bacterial vaccine compositions
TWI328035B (en) Anti-bacterial vaccine compositions
EP1914239B1 (fr) Bactérie négative à gramme attentuée
KR20160110368A (ko) 박테리아 표면 수용체 단백질로부터 유래된 면역원성 조성물 및 백신
ZA200408950B (en) Attenuated gram negative bacteria
WO2002077020A2 (fr) Genes de virulence dans h. influenzae

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230404